Application of toosendanin in inhibition of AURKA kinase

By inhibiting the protein level expression of AURKA kinase, the non-specificity and drug resistance of existing AURKA inhibitors are solved, and effective inhibition of AURKA is achieved, providing a potential more effective and specific cancer Treatment method.

CN118976032APending Publication Date: 2024-11-19GUANGZHOU MEDICAL UNIV +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411104228.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-16
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

Most of the existing AURKA inhibitors are ATP competitive inhibitors, which have nonspecific inhibitory side effects and drug resistance problems. The non-kinase activity of AURKA plays an important role in cancer, limiting its clinical application effect.

Method used

Using kenailin as a natural compound, it exerts a dose-dependent inhibitory effect by inhibiting the protein level expression of AURKA kinase, with potential lower risk of drug resistance and better specificity.

Benefits of technology

Citrustin significantly inhibits AURKA kinase at the nanomolar level, providing a potentially more effective and specific cancer treatment that reduces tumor cell proliferation and growth.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118976032A_ABST
    Figure CN118976032A_ABST
Patent Text Reader

Abstract

The invention provides application of toosendanin in inhibition of AURKA kinase, and belongs to the technical field of toosendanin application. The toosendanin disclosed by the invention can be used for remarkably reducing the expression of AURKA kinase at a protein level. According to the invention, the toosendanin is contacted with a target cell through a qPCR (quantitative polymerase chain reaction) experiment, a Western Blot experiment and an Immunofluoredox experiment, so that the toosendanin is proved to be capable of inhibiting the expression of AURKA kinase at a protein level in a dose-dependent manner.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of toosendan application, and in particular to the application of toosendan in inhibiting AURKA kinase. Background Art

[0002] AURKA, or AuroraA kinase, is a serine / threonine kinase that belongs to the Aurora kinase family. AURKA plays a key role in cell cycle regulation, especially in mitosis. AURKA plays an important role in the G2 / M transition of the cell cycle. Its abnormal expression will interfere with the function of the checkpoints in mitosis, leading to genetic instability and inducing tumor growth. Therefore, AURKA inhibitors are potential cancer treatment drugs.

[0003] Currently available AURKA inhibitors are almost all ATP-competitive inhibitors, which inhibit the kinase activity of AURKA by competitively binding to the binding site of ATP and AURKA kinase, and most of them are multi-inhibitors, with few selective inhibitors. Such inhibitors may produce non-specific inhibition on other kinases that bind to ATP, leading to side effects; and due to the heterogeneity and adaptability of tumor cells, long-term use of such inhibitors is prone to lead to the emergence of AURKA resistance. In addition, more and more studies have also shown that the non-kinase activity of AURKA also plays a huge role in cancer. These factors limit the clinical application effect of ATP-competitive AURKA inhibitors.

[0004] As an important source of drug development, natural compounds have the advantages of diverse structures, wide biological activities and relatively few side effects. Therefore, AURKA inhibitors obtained from natural compounds have great potential. By inhibiting the expression of AURKA protein at the transcriptional level, this class of compounds is expected to block the abnormal activation of AURKA kinase from the source, thereby more effectively inhibiting the proliferation and growth of tumor cells. Compared with traditional ATP competitive inhibitors, this transcriptional inhibition mechanism may have a lower risk of drug resistance and better specificity, bringing new inspiration and progress to cancer treatment research targeting AURKA.

[0005] In this context, searching for new compounds that have inhibitory effects on AURKA kinase has important scientific significance and clinical value. Summary of the invention

[0006] The purpose of the present invention is to provide the use of toosendan in inhibiting AURKA kinase, wherein the toosendan inhibits the expression of AURKA kinase gene in a dose-dependent manner at the protein level, and toosendan can exert a strong inhibitory effect on AURKA kinase at the nanomolar level.

[0007] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:

[0008] The present invention provides the use of toosendanin in inhibiting AURKA kinase.

[0009] Preferably, the toosendanin inhibits AURKA kinase by inhibiting its expression at the protein level.

[0010] Preferably, the method comprises: contacting toosendanin with target cells.

[0011] Preferably, the toosendanin can be used alone or in combination with other medicinal ingredients.

[0012] Preferably, the toosendanin can be made into tablets, capsules, granules, drops, granules or injections for use.

[0013] Preferably, the use of toosendan in inhibiting AURKA kinase includes the use of toosendan in preparing a drug for preventing and / or treating tumors.

[0014] The present invention also provides a medicine for preventing and / or treating tumors, preferably comprising toosendanin as an active ingredient.

[0015] Compared with the prior art, the toosendanin described in the present invention can inhibit the expression of AURKA kinase gene at the protein level in a dose-dependent manner, and toosendanin can exert a strong inhibitory effect on AURKA kinase at the nanomolar level. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] Figure 1 This is the map of the AURKA dual-luciferase reporter plasmid;

[0017] Figure 2 This is a diagram of the high-throughput screening results of the dual-luciferase experiment;

[0018] Figure 3 This is the result of the second round of screening in qPCR experiment;

[0019] Figure 4 It is the qPCR dose-effect curve diagram;

[0020] Figure 5 This is the result of Western Blot experiment;

[0021] Figure 6 This is the result of Immunofluorescence experiment. DETAILED DESCRIPTION

[0022] The present invention provides the use of toosendanin in inhibiting AURKA kinase.

[0023] The structural formula of toosendanin is:

[0024] In the present invention, the use of toosendan in inhibiting AURKA kinase is preferably:

[0025] The promoter base sequence of human AURKA was obtained from the NCBI database as shown in SEQ ID NO: 1;

[0026]

[0027] Designing PCR primers for amplifying SEQ ID NO: 1 and having MIul and BamH1 restriction sites; the PCR primers include SEQ ID NO: 2 and SEQ ID NO: 3;

[0028] The SEQ ID NO: 2 is cgacgacgcgtcatgctaagtactttgtaagc;

[0029] The SEQ ID NO: 3 is gcgggatcccctcgtccgccactgagatatc;

[0030] The PCR amplification products were obtained by PCR amplification using the whole genome DNA of 293T cells as a template; the synthesis of PCR amplification products was confirmed by agarose gel electrophoresis;

[0031] The PCR amplification product was inserted into the dual-luciferase reporter vector through the two restriction sites of MIul and BamH1, and sequencing confirmed that the AURKA dual-luciferase reporter plasmid was successfully constructed. Figure 1 As shown;

[0032] The dual luciferase reporter vector of the present invention was purchased from Beijing Qingke Biotechnology Co., Ltd.; the sequencing can be performed using technical means well known to those skilled in the art.

[0033] 293T cells in logarithmic growth phase were cultured at 4×10 6 The number of cells / ml was evenly spread in a 10 cm medium dish and cultured in a 37°C, 5% CO2 cell culture incubator for 24 hours;

[0034] A transfection system was configured to conduct a transfection experiment; the transfection system included tube A and tube B, wherein tube A included 500 μM opti-mem and 24 μM PEI, and tube B included 500 μM opti-mem and 12 μM AURKA dual luciferase reporter plasmid. Tube A and tube B were mixed evenly, incubated at room temperature for 15 minutes, and after 15 minutes, the transfection system was evenly added to 293T cells, and the solution was changed after 8 hours;

[0035] After 24 hours, 293T was digested and 1×10 4 293T cells transfected with AURKA dual-fluorescence reporter plasmid were plated in 96-well plates at a density of 10 cells per well and cultured in a cell culture incubator at 37°C and 5% CO2 for 12 hours;

[0036] After 12 hours of culture, 10 μM of the compound was added according to the screening dose recommended by the natural compound library L6000; the natural compound library L6000 was purchased from Shanghai Taoshu Biotechnology Co., Ltd.

[0037] After 24 hours, the cells were lysed and the drugs were screened by high-throughput dual-luciferase assay, specifically:

[0038] (1) Discard the cell culture medium, wash the cells twice with PBS, add 50 μL of cell lysis buffer to each well, and lyse on ice for 5 minutes;

[0039] (2) After lysis is complete, take 20 μL of lysis solution and add it to the ELISA plate;

[0040] (3) preparing firefly luciferase reaction working solution and Renilla luciferase reaction solution, namely, diluting firefly luciferase substrate (50×) and Renilla luciferase substrate (50×) with corresponding buffer to 1× working solution, and incubating to room temperature;

[0041] (4) Add 100 μL of firefly luciferase reaction solution to the ELISA plate, shake the plate to mix, and detect the activity of firefly luciferase;

[0042] (5) Add 100 μL of Renilla luciferase reaction solution, shake the plate to mix, and detect the activity of Renilla luciferase.

[0043] The final experimental results were calculated according to the dual luciferase reporter assay as follows: experimental group ratio = (experimental group F-background F) / (experimental group R-background R); control group ratio = (control group F-background F) / (control group R-background R); expression fold = experimental group ratio / control group ratio;

[0044] Finally, 36 candidate compounds that can inhibit AURKA expression at the transcriptional level were screened through dual luciferase assay, such as Figure 2 shown.

[0045] Second round of screening by qPCR experiment:

[0046] (1) PC9 lung cancer cells in logarithmic growth phase were cultured at 2.5×10 5 The cells were seeded at a density of 100 in a 12-well plate and cultured in a 37°C, 5% CO2 cell culture incubator for 24 hours;

[0047] (2) 24 hours later, the 36 compounds obtained from the above screening were added to the cell culture medium at a concentration of 10 μM and cultured in a cell culture incubator at 37° C. and 5% CO 2 for 24 hours;

[0048] (3) After 24 hours, the cell plate was removed from the incubator, the culture medium was discarded, and the cells were washed twice with PBS;

[0049] (4) Extract RNA according to the steps in the RNA extraction kit manual, specifically: add 500 μL of lysis solution to each well, repeatedly blow and lyse the cells, and leave at room temperature for 5 minutes; after complete lysis, take all the lysis solution, add it to a 1.5 mL centrifuge tube, add an equal volume of anhydrous ethanol, blow and mix, and obtain a mixed solution; take 600 μL of the mixed solution and add it to the RNA purification column, centrifuge at 12000r for 1 minute, then discard the liquid in the collection tube, add 500 μL of wash buffer, and centrifuge at 12000r for 1 minute; discard the liquid in the collection tube, centrifuge at 12000r again for 1 minute, and open the cover for 2 minutes to dry; transfer the adsorption column to a new 1.5 mL centrifuge tube, add 30 μL of DEPC water on the membrane, and centrifuge at 12000r for 1 minute;

[0050] (5) Open the Nano Drop ONE ultraviolet spectrophotometer, select "RNA" on the "Nucleic Acids Tab" page, and measure and record the concentration of the liquid in the collection tube in turn;

[0051] (6) Take eight tubes and add DEPC water, RNA and DNAase (5×) in sequence. The total mass of the system is 800 ng and the total volume is 15 μL. Turn on the MiniAmp Plus PCR thermal cycler, put in the eight tubes, select the set method, run the instrument, add 5 μL of reverse transcription reagent after incubation, and select the set method for incubation.

[0052] (7) Make three replicate wells for each group, with 5 μL SYBR Green, 3.2 μL DEPC water, 1 μL cDNA and 0.8 μL mixed primers in each well, prepare the solution and load the sample. Centrifuge after film application, turn on the real-time fluorescence quantitative PCR instrument (Roche), open the software admin, select the method, put the well plate into the instrument, and click run.

[0053] Finally, the final experimental results were calculated according to the qPCR experiment. The method is as follows: ΔCT = target gene CT value - mean CT value of internal reference gene; ΔΔCT = experimental group ΔCT - mean ΔCT of control group. 2 -ΔΔCT value.

[0054] Finally, 10 Chinese medicine monomer compounds that can inhibit AURKA expression at the gene transcription level were obtained. Figure 3The compounds include compound No. 330: 10-hydroxydecanoic acid, compound No. 900: γ-mangostin, compound No. 991: icariin, compound No. 1048: trifoliate, compound No. 1289: yellow kava piperine A, compound No. 1362: cinnamyl acetate, compound No. 1366: palmitic acid, compound No. 1376: toosendanin, compound No. 1399: 7-demethyl cypermethrin, and compound No. 1430: 7-hydroxycoumarin.

[0055] The structural formula of the compound No. 330, 10-hydroxydecanoic acid, is:

[0056] The structural formula of the compound No. 900, γ-mangostin, is: The structural formula of the compound No. 991, icariin, is: The structural formula of the compound No. 1048, trilobatin, is: The structural formula of the compound No. 1289, yellow kava piperine A, is: The structural formula of the compound No. 1362, cinnamyl acetate, is: The structural formula of the compound No. 1366, palmitic acid, is: The structural formula of the compound No. 1399 7-demethyl cyperus rotundus is:

[0057] The structural formula of the compound No. 1430, 7-hydroxycoumarin, is:

[0058] The effective half concentration of toosendanin was detected by qPCR experiment, specifically:

[0059] PC9 lung cancer cells were plated at 2.5 × 10 5 The cells were inoculated at a density of 10 μM, 5 μM, 2.5 μM, 1.25 μM, 0.625 μM, 0.3125 μM, 0.15625 μM, and 0.078125 μM in different concentrations of toosendan for 24 hours. qPCR experiments were performed according to the above steps, and the effective half concentration of toosendan for inhibiting AURKA gene expression was 52.72 nM. Figure 4 shown.

[0060] Based on the above, it can be seen that toosendanin can inhibit the expression of AURKA kinase.

[0061] In the present invention, the toosendanin is preferably used alone or mixed with other medicinal ingredients.

[0062] In the present invention, the toosendanin can be preferably made into tablets, capsules, granules, drops, granules or injections for use.

[0063] In the present invention, the use of toosendan in inhibiting AURKA kinase preferably includes the use of toosendan in preparing a drug for preventing and / or treating tumors.

[0064] The present invention also provides a medicine for preventing and / or treating tumors, preferably comprising toosendanin as an active ingredient.

[0065] In the present invention, unless otherwise specified, the required instruments or technical means may be those well known to those skilled in the art.

[0066] The technical solutions provided by the present invention are described in detail below in conjunction with the embodiments, but they should not be construed as limiting the protection scope of the present invention.

[0067] Example 1

[0068] Western Blot assay was used to detect the inhibition of AURKA expression by Toosendanin at the protein level

[0069] 1. PC9 lung cancer cells in logarithmic growth phase were cultured at 2.5×10 5 The cells were seeded at a density of 100 cells / mL in a 6-well plate and cultured in a 37°C, 5% CO2 cell culture incubator for 24 hours.

[0070] 2. Treated with different concentrations of Toosendanin, the experimental group drugs were diluted with DMSO; the drug concentration was set to 12.5nM, 25nM, 50nM, 100nM, 200nM, and then placed in a 37°C, 5% CO2 cell culture incubator for culture;

[0071] 3. Protein extraction:

[0072] (1) Discard the cell culture medium, wash the cells twice with PBS, add 100 μL of cell lysis buffer to each well, and lyse on ice for 10 minutes;

[0073] (2) After lysis is complete, take the lysate and add it to a 1.5 mL centrifuge tube;

[0074] (3) Place the centrifuge tube in ice and sonicate first and then vortex for three times, each time for 10 minutes;

[0075] (4) Place the centrifuge tube in a precooled centrifuge and centrifuge at 4°C and 12,000 rpm for 10 minutes. Take the supernatant and transfer it to a new 1.5 mL centrifuge tube.

[0076] (5) Protein concentration was measured by BCA method with a sample loading of 30 μg;

[0077] (6) Add Loading Buffer (5×) at a ratio of 4:1, vortex to mix thoroughly, boil in a water bath at 100°C for 5 min, and cool on ice.

[0078] 4. Install the prefabricated membrane (the prefabricated membrane comes from Biyuntian Biotechnology Co., Ltd.) on the electrophoresis accessories, pour the electrolytic powder into 1L of pure water and mix well, pour the electrolyte into the electrophoresis tank, and slowly pull out the comb vertically;

[0079] 5. Add 20μL loading buffer, 4μL marker, 20μL protein sample, 4μL marker and 4μL marker to the sample wells from left to right, then pour half a box of electrolyte into the outer box, connect the power supply, set it to 80V constant voltage, and run for 90 minutes;

[0080] 6. Soak the splint, sponge and cotton in the frozen transfer solution, remove the precast gel from the box, cut off the excess edges with a scraper, put the gel on the cotton in the transfer solution, cover the gel with the PVDF membrane soaked in methanol, remove the bubbles, cover with cotton and sponge, and close the splint;

[0081] 7. Place the splint into the assembly, put it into the box and fill it with transfer solution, put it into the ice box, place the box in the ice, connect the power supply, set 100V constant current, and run for 120 minutes;

[0082] 8. Remove the splint, take out the PVDF membrane with a clamp and put it into a clean and dry empty box, take 2g of skim milk powder (the skim milk powder is from Biyuntian Biotechnology Co., Ltd.) and add it to 40ml TBST, pour the prepared skim milk into the box, and place it on a shaker at 40r for 2 hours;

[0083] 9. Discard skim milk, add TBST and shake on a shaker at 120r for 5 minutes to wash, repeat three times, take out the membrane, cut it, put it into different grids, pour GAPDH (1:1000), AURKA (1:1000), AURKB (1:1000) antibodies respectively, and put it in a refrigerator at 4°C overnight;

[0084] 10. Recover the primary antibody, wash three times with TBST, add the secondary antibody, and incubate on a shaker at 40r for 2 hours;

[0085] 11. Recover the secondary antibody, wash three times with TBST, place the membrane on the instrument for exposure, calculate the gray value of the corresponding band using ImageJ software, and perform statistical analysis on the absorbance ratio with the internal reference GAPDH, such as Figure 5 shown.

[0086] Example 2

[0087] Immunofluorescence assay was used to detect the inhibition of AURKA expression by toosendanin at the protein level

[0088] 1. PC9 lung cancer cells in logarithmic growth phase were cultured at 1×10 5 The cells were inoculated at a density of 100 cells / mL in a confocal dish and cultured in a cell culture incubator at 37°C and 5% CO2 for 24 hours.

[0089] 2. Treated with different concentrations of Toosendanin, the experimental group drugs were diluted with DMSO, the drug concentration was set to 25nM, 50nM, 100nM, and then placed in a 37°C, 5% CO2 cell culture incubator for culture;

[0090] 3. Aspirate the culture medium, wash three times with PBS, add 400 μL of frozen 4% paraformaldehyde to each well and fix in a 4°C refrigerator for 20 minutes. After rewarming for 5 minutes, aspirate the waste liquid and wash three times with PBS;

[0091] 4. Add 400 μL of 0.5% Triton-100 (1:200) prepared with PBS to each well, incubate at room temperature for 20 minutes, and wash three times with PBS;

[0092] 5. Add 400 μL of 5% blocking goat serum (1:20) prepared with PBS to each well, block for 1 hour at room temperature, and wash three times with PBS;

[0093] 6. Add 400 μL of primary antibody to each well and place in a refrigerator at 4°C overnight;

[0094] 7. Rewarm the sample for 30 minutes, recover the primary antibody, and wash three times with PBS;

[0095] 8. Pour in the secondary antibody and place in a 37°C shaker for 1 hour;

[0096] 9. Discard the secondary antibody and wash three times with PBS;

[0097] 10. Add FITC, incubate at 37°C for 30 minutes, discard FITC and wash three times with PBS;

[0098] 11. Add DAPI, incubate at 37°C for 10 minutes, discard FITC and wash three times with PBS;

[0099] 12. Add 2 drops of 10% glycerol and place in a refrigerator at 4°C overnight;

[0100] 13. Place the confocal dish under a confocal microscope and take pictures. Use ImageJ software to perform fluorescence quantitative analysis on the fluorescence images. Figure 6 shown.

[0101] in conclusion

[0102] (1) In Example 1, a Western Blot experiment was performed to detect that Toosendan inhibited the expression of AURKA at the protein level. The test results were as follows: Figure 5 Based on Figure 5 It can be seen that Toosendanin can inhibit the expression of AURKA at the protein level in a dose-dependent manner;

[0103] (2) In Example 2, the Immunofluorescence experiment was used to detect that Toosendan inhibited the expression of AURKA at the protein level. The test results were as follows: Figure 6 Based on Figure 6 It can be seen that toosendan can inhibit the expression of AURKA at the protein level in a dose-dependent manner.

[0104] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. Application of toosendanin in inhibiting AURKA kinase.

2. The use of Toosendanin in inhibiting AURKA kinase according to claim 1, characterized in that: The toosendanin inhibits AURKA kinase by inhibiting its expression at the protein level.

3. The use of Toosendanin in inhibiting AURKA kinase according to claim 1, characterized in that: include: The toosendanin is brought into contact with target cells.

4. The use of Toosendanin in inhibiting AURKA kinase according to claim 1, characterized in that: The toosendanin is used alone or in combination with other medicinal ingredients.

5. The use of Toosendanin in inhibiting AURKA kinase according to claim 1, characterized in that: The toosendanin can be made into tablets, capsules, granules, drops, granules or injections for use.

6. The use of Toosendanin in inhibiting AURKA kinase according to claim 1, characterized in that: The application of toosendan in inhibiting AURKA kinase includes the application of toosendan in preparing drugs for preventing and / or treating tumors.

7. A drug for preventing and / or treating tumors, characterized in that: Contains the active ingredient toosendanin.